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Objective: This study was designed to evaluate the long-term safety and effectiveness of repeated doses of
the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of patients
with OA knee pain.
Design: The current study (clinicaltrials.gov identiﬁer: NCT00399490) was a multicenter, phase II, open-
label, multiple-dose extension of an earlier randomized clinical trial. All patients (N¼ 281) received
infusions of tanezumab 50 mg/kg on Days 1 and 56 with subsequent doses administered at 8-week
intervals (up to a total of eight infusions). The primary endpoint of this study was safety. Effectiveness
evaluations included overall knee pain, Western Ontario and McMaster Universities Osteoarthritis
(WOMAC) index subscales, and subject global assessment (SGA) of response to therapy on 0e100 point
visual analog scales.
Results: Repeated administration of tanezumab resulted in a low incidence of treatment-related adverse
events (AEs; 7.5%). The rate of serious AEs was also low (2.8%) with none considered treatment-related.
Few AEs of abnormal peripheral sensation were reported; hypoesthesia was reported by nine patients
(3.2%), paresthesia by seven patients (2.5%), and hyperesthesia, peripheral neuropathy, and sensory
disturbance were each reported by one patient (0.4% for each). Most AEs of abnormal peripheral
sensation were rated as mild (95%) and the majority (65%) resolved before study completion. At Week 8,
overall knee pain and SGA improved from baseline by a mean (standard error) of 12.8 (1.78) and 8.0
(1.66), respectively. Similar improvements occurred for WOMAC subscales.
Conclusions: Repeated injections of tanezumab in patients with moderate to severe knee OA provide
continued pain relief and improved function with a low incidence of side effects. Additional studies to
deﬁne the efﬁcacy and duration of pain reduction and to provide a more complete assessment of long-
term safety are warranted.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) of the knee is a major cause of chronic
musculoskeletal pain often associated with signiﬁcant impairment
and functional disability1,2. Individuals with advanced knee OA
frequently have pain when walking with reduced range of motion
and chronic inﬂammation in the affected joint3. CurrentT.J. Schnitzer, Northwestern
oom 1020, 710 N. Lake Shore
ax: 1-312-503-1505.
er).
s Research Society International. Precommendations for the management of knee OA include phar-
macologic therapies as well as nonpharmacologic therapies such as
weight loss in overweight patients and low-impact aerobic,
strengthening, and range-of-motion exercises2,4,5. Recommended
pharmacologic therapies include analgesics, nonsteroidal anti-
inﬂammatory drugs (NSAIDs), low potency opioids, and narcotic
analgesics2,4,6. Although these agents may provide some relief of
the knee pain, many patients ﬁnd that satisfactory pain control is
not achieved6. In addition, several therapies have safety or tolera-
bility concerns such as cardiovascular or gastrointestinal risks,
delayed onset of relief, and risk of dependence or addiction2,6.
Targeting of novel speciﬁc modulators of painmay be ameans to
improve efﬁcacy and safety of pharmacologic therapies for the
treatment of OA pain. One such target is nerve growth factor (NGF),ublished by Elsevier Ltd. All rights reserved.
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Fig. 1. Patient disposition.
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the pathophysiology of pain7,8. While NGF supports development of
the sensory nervous system during neonatal stages, in adults the
role of NGF appears to be modulation of nociceptor function8,9. In
several chronic pain conditions such as interstitial cystitis, OA,
rheumatoid arthritis, and psoriasis/psoriatic arthritis, elevated NGF
levels are associated with increased pain8,10 whereas decreases in
NGF have been associated with a reduction of pain response8. In
addition, NGF levels are increased in the synovial ﬂuid of OA
patients compared with synovial ﬂuid from healthy patients11.
Inhibition of NGF results in a signiﬁcant reduction in pain behavior
in an animal model of skeletal pain12. Therefore, therapeutic agents
that speciﬁcally result in decreased NGF activity may be able to
provide relief in many types of pain, including OA.
Tanezumab, a humanized anti-NGF monoclonal antibody that
has a high speciﬁcity and afﬁnity for NGF and blocks the binding of
NGF to its receptors, TrkA and p7513, is currently under investiga-
tion for the treatment of several types of chronic pain8. An initial,
small, placebo-controlled, randomized, double-blind study
indicated that tanezumab at doses of 100e300 mg/kg was effective
and well tolerated in the treatment of OA knee pain14,15. The
ensuing phase II study (Study 1008, clinicaltrials.gov identiﬁer:
NCT00394563) showed reduced knee pain over 16 weeks following
tanezumab treatment (10e200 mg/kg, two intravenous [IV] infu-
sions at 8-week intervals) to patients with knee OA for whom non-
opiate pain medications failed or who were considered candidates
for invasive intervention16. During that study, abnormal peripheral
sensory symptoms that are associated with large-ﬁber sensory
function such as paresthesia and hypoesthesia were noted16. The
majority of these cases were generally transient in nature and not
associated with persistent neurologic changes or altered cogni-
tion16. The current study (Study 1009, clinicaltrials.gov identiﬁer:
NCT00399490) is the extension of Study 1008 and was designed to
evaluate the long-term safety and effectiveness of multiple, repeat
doses of tanezumab during open-label treatment of patients with
OA knee pain.
Method
Study design and selection of participants
Study 1009 was a multicenter, phase II, open-label, multiple-
dose extension study enrolling patients who had previously
participated in studies of tanezumab for the treatment of OA. This
study was conducted in compliance with the Declaration of
Helsinki and with all International Conference on Harmonization
Good Clinical Practice guidelines. Investigators at 28 centers in the
United States participated in the study. The study protocol and
amendments were reviewed by an Institutional Review Board. Each
subject provided written informed consent prior to study
participation.
Inclusion criteria for the current study (Study 1009) included
enrollment in Study 1008 in which the subjects had received two
infusions of tanezumab and had been followed for 8 weeks after
their last infusion or had been enrolled in Study 1008 and had
prematurely discontinued due to lack of efﬁcacy and had been
followed for8 weeks after their last infusion. Eligibility criteria for
participation in Study 1008 have been previously published16. In
brief, patients with OA in this study were aged 40e75 years and
were unwilling to take or had an unsatisfactory response to non-
opiate pain medications or were candidates for or seeking invasive
interventions such as intra-articular injections or total knee
replacement16. At screening and baseline (post-washout of pain
medications), knee pain had to be moderate to severe in intensity
(50 to 90) based on a 0e100 point visual analog scale (VAS) forWestern Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) subscale item “walking pain on a ﬂat surface”17.
Key exclusion criteria for Study 1009 included pregnancy or
lactation, history or symptoms of autoimmune disorders, cancer
within the last 5 years (except for cutaneous basal cell or squamous
cell cancer resolved by excision), allergic or anaphylactic reaction to
a monoclonal antibody or IgG-fusion protein, hepatitis B or C,
human immunodeﬁciency virus (HIV) infection, drug abuse,
ﬁbromyalgia, clinically signiﬁcant cardiac disease, diabetes mellitus
requiring oral hypoglycemic agents or insulin, clinically signiﬁcant
neurologic disease, or clinically signiﬁcant psychiatric disorder.
Patients were also excluded from Study 1009 if they experienced
moderate to severe abnormal pain sensations, such as dysesthesia
or paresthesia that the investigator considered related to study
drug in Study 1008 and were unresolved at the time of enrollment
in Study 1009; severe pain sensations considered related to tane-
zumab and resulted in termination in Study 1008; or any adverse
event (AE) or condition during controlled tanezumab studies that,
in the opinion of the investigator, excluded the patient from
participating in the open-label extension.
At screening, patients reported their medical history and
underwent a physical and neurologic examination, including vital
signs, 12-lead electrocardiogram (ECG), routine laboratory tests,
pregnancy testing, urine drug screen, and concomitant medication
use. The Hopkins Verbal Learning Test-Revised (HVLT-R), a brief,
repeatable, verbal learning and memory test used as a measure of
learning norms, stability, and delayed recall to assess abnormal
forgetting18, also was administered. Blood samples were collected
for pharmacokinetic analysis and to screen for antitanezumab
antibodies (neutralizing human antihuman antibodies). Patients
did not undergo screening if they enrolled in Study 1009 within 30
days of the termination visit in Study 1008. For those patients, data
from the termination visit were entered for the screening visit
except for medical history, urine drug screen, demography and
X-ray, whichwere completed as part of Day 1 and the patient had to
undergo hepatitis and HIV screening panel prior to Day 1. Imme-
diate enrollment into Study 1009 was not necessary; therefore the
time after completion of Study 1008 and enrollment in Study 1009
varied (mean and median time from last day in Study 1008 to ﬁrst
dose in Study 1009 was 13 and 7 days, respectively).
All patients in the current study were scheduled to receive
infusions of tanezumab 50 mg/kg (5 mL normal saline administered
IV over 5 min) on Study 1009 Days 1 and 56 in an open-label
manner regardless of their assigned treatment group in Study 1008.
Subsequent doses of tanezumab were administered at 8-week
Table I
Subject baseline and demographic characteristics
Study 1008 treatment All treatments Study
1009 (n¼ 281)
Tanezumab dose
Placebo
(n¼ 42)
10 mg/kg
(n¼ 47)
25 mg/kg
(n¼ 49)
50 mg/kg
(n¼ 49)
100 mg/kg
(n¼ 47)
200 mg/kg
(n¼ 47)
Age, mean SD, y 57.9 7.9 59.2 8.5 60.7 7.9 60.2 7.9 58.5 8.4 59.4 7.9 59.3 8.1
Male, n (%) 19 (45.2) 16 (34.0) 14 (28.6) 21 (42.9) 18 (38.3) 22 (46.8) 110 (39.1)
Race, n (%)
White 35 (83.3) 40 (85.1) 47 (95.9) 43 (87.8) 43 (91.5) 43 (91.5) 251 (89.3)
Black 5 (11.9) 3 (6.4) 0 2 (4.1) 1 (2.1) 4 (8.5) 15 (5.3)
Asian 2 (4.8) 1 (2.1) 0 0 2 (4.3) 0 5 (1.8)
Other 0 3 (6.4) 2 (4.1) 4 (8.2) 1 (2.1) 0 10 (3.6)
Weight, mean SD, kg 93.3 17.7 89.3 19.8 90.2 16.2 87.0 19.7 93.0 17.5 91.9 16.7 90.7 18.0
Height, mean SD, cm 169.3 9.4 167.9 10.7 167.9 9.4 168.0 11.1 169.9 9.5 170.7 10.7 168.9 10.1
Baseline overall knee pain*,
mean SD
68.5 9.7 70.5 8.3 70.2 11.1 67.3 11.2 70.4 10.3 70.8 9.6 69.6 10.1
* As measured on VAS, 0e100 in the ITT population.
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the study was still ongoing. The study was completed when the last
patient who entered the study had received at least two doses and
completed the 12-week follow-up period for safety assessments.
Thus, not all patients were treated with the same number of study
medication infusions or for the same amount of time.Table II
No. of patients receiving each infusion during Study 1009
Administration No. of patients (%)Study assessments
On Day 1 of Study 1009, patients underwent physical and
neurologic evaluations. In addition, patients were asked to evaluate
overall index knee pain, subject global assessment (SGA) of
response to therapy, and to complete the WOMAC on VAS scales
(0e100 point scale; 0 indicates “no pain” and 100 indicates
“extreme pain” on the pain assessments and 0 indicates “very poor”
and 100 indicates “very good” on the SGA). These tests were used to
establish baseline values and were performed prior to the admin-
istration of the ﬁrst infusion of tanezumab.
Follow-up evaluations were scheduled for Day 28, Day 56, and at
each subsequent dosing visit at 8-week intervals, with the termi-
nation visit scheduled 12 weeks after the last dose. At each of these
visits, patients underwent safety and effectiveness analyses. Safety
analyses included all observed or volunteered AEs, including
severity, investigator’s opinion of relationship to study drug, and
outcome; serious AEs (SAEs); blood tests; urinalysis; vital signs;
ECG; HVLT-R; and physical and neurologic examinations. Effec-
tiveness evaluations included overall knee pain, WOMAC subscales
(Pain, Physical Function, and Stiffness), and SGA. The primary
outcome of Study 1008, knee painwhile walking on a ﬂat surface16,
was evaluated only as part of the WOMAC subscales in Study 1009.
Blood samples were collected and serum was analyzed for the
presence of antitanezumab antibodies using a validated non-
bridging facilitated allergen binding (Fab) assay following a tiered
approach using screening, conﬁrmation, and titer/quantitation. Any
serum samples positive for antitanezumab antibodies were further
characterized for the presence of neutralizing antitanezumab
antibodies using a validated electrochemiluminescent
immunoassay.Infusion 1 281 (100.0)
Infusion 2 (Week 8) 251 (89.3)
Infusion 3 (Week 16) 180 (64.1)
Infusion 4 (Week 24) 121 (43.1)
Infusion 5 (Week 32) 89 (31.7)
Infusion 6 (Week 40) 62 (22.1)
Infusion 7 (Week 48) 28 (10.0)
Infusion 8 (Week 56) 6 (2.1)Statistical analyses
The safety analysis was conducted based on the safety pop-
ulation, which was deﬁned as subjects who received1 study drug
infusion during Study 1009. Summary statistics (mean, n, SD, S.E.M.,
median, and range) were calculated for the effectiveness end pointson the intent-to-treat (ITT) population, which was deﬁned as
subjects who received 1 study drug infusion and had 1 evalu-
ation post-infusion in Study 1009. No statistical inferential tests
were undertaken for the analysis of effectiveness in this study.
Results
Similar numbers of patients from each of the Study 1008
treatment groups continued treatment during the open-label
extension study. Of the 281 patients who received tanezumab
treatment, 183 (65.1%) patients completed the study while 98
(34.9%) discontinued (Fig. 1). Patient demographic and baseline
characteristics were similar regardless of which treatment patients
received in Study 1008 (Table I). The mean (SD) age of patients
was 59.3 (8.1) years and the majority of patients were female
(60.9%). Patients received between one and eight infusions of
50 mg/kg tanezumab (Table II) over a mean (SD) period of 224
(117) days (median duration 198 days; range 1 e 484 days). The
last patients who were treated in Study 1009 received their last
dose on November 14, 2007. At this point, there was no further
treatment for the ongoing patients in the study. Sixty-seven
percent of patients (188/281) were in the study at this point. Thus,
not all patients received 56 weeks (eight infusions) of tanezumab
treatment.
Safety evaluations
Repeated doses of 50 mg/kg tanezumab resulted in 7.5% of
patients reporting an AE that was considered related to tanezumab
treatment (Table III). The rate of SAEs was low (2.8%) and none of
the SAEs were considered treatment-related. Therewere no deaths,
dose reductions, or temporary discontinuations due to treatment-
emergent AEs. No vital sign or physical or neurologic examination
Table III
Treatment-emergent AEs, all cause
n (%)
Patients reporting
Any AE 168 (59.8)
Treatment-related AE 21(7.5)
SAE* 8 (2.8)
Most common AEs
Arthralgia 19 (6.8)
Back pain 17 (6.0)
Headache 16 (5.7)
AEs of abnormal peripheral sensation
Hyperesthesia 1 (0.4)
Hypoesthesia 9 (3.2)
Neuropathy peripheral 1 (0.4)
Paresthesia 7 (2.5)y
Sensory disturbance 1 (0.4)
Discontinued due to AE 19 (6.8)
* None were judged by the investigator as treatment-related.
y Patients were counted only once in each row, although
paresthesia occurred twice in one patient.
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term learning and memory, showed that no notable change in total
or delayed recall was observed over the course of the study.
Approximately 7% of the study patients discontinued due to AEs,
and only 1.4% of patients discontinued tanezumab infusions due to
a treatment-related AE.
Individual AEs of abnormal peripheral sensation, such as
paresthesia and hypoesthesia, were reported by less than 5% of
patients (Table III) and most (95%) events were rated as mild.
Peripheral neuropathy (a progressing median neuropathy [carpal
tunnel syndrome]) was severe in one patient, although this was
reported by the site investigator as not related to study medication.
Most AEs of abnormal peripheral sensation (65%) resolved before
study completion and lasted for a median duration of 10 days,
whereas the median duration of AEs that did not resolve before
study completion was 87 days (Fig. 2). In Study 1009, no patients
reported allodynia or dysesthesia.k e e W 
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Fig. 2. Onset and offset of 20 AEs of abnormal peripheral sensation experienced by 18 pat
*One patient experienced one event of hypoesthesia and one event of paresthesia; yone p
peripheral sensation rated as severe, all others were mild. Onset and offset of AEs of a
(continuing AE). Patient time in the study is depicted by the dashed line.A comparison of patients who had received placebo during
Study 1008 vs patients who had received tanezumab noted no
differences in the rates or types of AEs, including AEs of abnormal
peripheral sensation, between groups. In addition, the number of
patients experiencing and types of AEs was generally consistent
regardless of the number of tanezumab infusions patients received
during Study 1009 and the incidence of AEs of abnormal peripheral
sensation for Weeks 1e8 (0e1.1%) was similar to each subsequent
8-week interval (Weeks 9e16: 0e0.4%; Weeks 17e24: 0e0.9%;
Weeks 25e32: 0e0.6%; Weeks 33e40: 0e1.7%; Weeks 41e48:
0e2.3%; Weeks 49e56: 0%; Weeks 57: 0%).
Three samples from two patients were positive for anti-
tanezumab antibodies. The tanezumab pharmacokinetic proﬁles
for these patients were similar to patients negative for anti-
tanezumab antibodies (data not shown). AEs experienced by the
two antitanezumab antibody-positive patients were rated as mild,
resolved before study completion, and were considered not related
to the study drug.
Effectiveness evaluations
Patients who had previously received lower doses of tanezumab
(10 or 25 mg/kg) or placebo during Study 1008 reported a reduction
in pain when switching to the standardized 50-mg/kg dose of
tanezumab during Study 1009; this improved effectiveness was
maintained for the duration of the study. For patients who received
50 mg/kg tanezumab during both studies, pain relief was main-
tained across studies. In contrast, patients who had received higher
doses of tanezumab in Study 1008 reported decreased effectiveness
(29.9% and 78.2% increase in mean overall pain scores, 100 and
200 mg/kg, respectively) at Week 8 of the current study following
the switch to 50 mg/kg, consistent with a doseeresponse in effec-
tiveness with reduction in tanezumab dose from Study 1008 to
Study 1009. Mean pain scores between Weeks 8 and 32 were
similar regardless of treatment received in Study 1008. Mean
(S.E.M. [95% conﬁdence interval] effect size) change in overall
knee pain relative to Study 1008 baseline (for all patients evaluated
within 70 days of last dose) was 34.4 (1.76 [37.90, 30.96]2 7 4 6 6 5 8 4 0 4 
ients in Study 1009.
atient experienced two paresthesia events; zthis event was the only AE of abnormal
bnormal peripheral sensation are denoted by hatched bars (resolved AE) or arrows
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Fig. 3. Mean (S.E.M.) change from 1008 baseline in weekly overall OA knee pain intensity in index knee for all patients in the ITT population reporting within 70 days of last dose.
All patients received IV infusions of 50 mg/kg tanezumab upon rollover from Study 1008. Arrows depict when tanezumab was administered (8-week intervals; two infusions in
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[16.34, 9.33] 0.47) compared to Study 1009 baseline at 8
weeks after the ﬁrst tanezumab infusion (Fig. 3). The overall
improvement in knee pain was maintained for up to 1 year during
the open-label treatment with tanezumab 50 mg/kg, with a mean
change from Study 1008 baseline in overall knee pain of 26.0
(8.99 [47.25, 4.73] 1.02) and from Study 1009 baseline
of 11.5 (9.13 [33.08, 10.08] 0.45) at Week 56 in Study 1009.
The change in dose from Study 1008 to Study 1009 also produced
similar changes in other measures of effectiveness, including SGA
and WOMAC physical function score (Table IV).
There was no evidence of tolerance or loss of response, since
a consistent improvement in the mean change from baseline wasnoted for the duration of the study for all of the effectiveness
measures. Few patients (11%) discontinued due to lack of effec-
tiveness, indicating that treatment had a persistent beneﬁcial
effect.
Discussion
Repeated administration of tanezumab 50 mg/kg in this study of
patients with moderate to severe OA knee painwas associated with
no serious safety concerns. The types of AEs seen during this long-
term open-label extension study were not different from those
observed during the short-term treatment in Study 100816. The
incidence of AEs did not increase with the number of infusions;
Table IV
Mean SD baseline and change from baseline (with 95% conﬁdence intervals) and effect size in SGA and WOMAC physical function scores
Study 1008 treatment All treatments Study
1009 (n¼ 277)
Tanezumab dose
Placebo
(n¼ 40)
10 mg/kg
(n¼ 47)
25 mg/kg
(n¼ 48)
50 mg/kg
(n¼ 49)
100 mg/kg
(n¼ 47)
200 mg/kg
(n¼ 46)
SGA*
1008 baseline 49.5 19.6 55.7 19.3 53.4 20.6 52.9 16.3 50.7 20.0 54.2 22.4 52.8 19.7
Change from 1008 baseline to:
1008 endpoint 11.3 23.2 5.3 27.2 20.6 29.0 19.3 27.5 25.1 25.3 21.3 35.6 17.6 29.1
1009 baseline 56.4 21.3 61.7 19.3 61.2 22.9 60.2 23.2 65.5 24.8 71.1 20.4 62.8 22.3
Change from 1009 baseline to:
1009 Week 4 19.1 23.6
(10.98, 27.19)
0.81
14.3 20.6
(8.15, 20.52)
0.70
9.1 30.9
(0.41, 18.59)
0.29
14.1 26.9
(5.75, 22.53)
0.53
3.8 27.0
(4.39, 12.03)
0.14
2.2 24.4
(5.63, 9.98)
0.09
10.3 26.2
(6.98, 13.53)
0.39
1009 Week 8 15.3 24.5
(6.83, 23.68)
0.62
12.5 24.3
(4.71, 20.24)
0.51
14.1 26.6
(6.00, 22.14)
0.53
3.6 25.8
(4.64, 11.84)
0.14
5.9 26.1
(2.19, 14.05)
0.23
3.7 22.1
(11.10, 3.64)
0.17
8.0 25.6
(4.74, 11.28)
0.31
1009 Week 32 0.4 27.9
(14.01, 14.72)
0.01
10.8 16.6
(2.29, 19.35)
0.65
15.7 29.2
(1.98, 29.32)
0.54
9.4 42.3
(20.88, 39.68)
0.22
6.3 27.9
(8.60, 21.10)
0.22
3.0 17.0
(20.81, 14.81)
0.18
7.9 27.7
(1.95, 13.84)
0.28
WOMAC physical functiony
1008 baseline 67.8 13.2 64.2 11.8 69.5 14.0 63.9 13.0 67.8 15.0 68.1 14.3 66.9 13.7
Change from 1008 baseline to:
1008 endpoint 21.1 24.8 23.0 22.3 32.4 26.6 31.7 25.1 41.4 22.5 47.3 21.7 33.7 25.3
1009 baseline 52.3 22.4 50.1 21.7 49.9 26.4 42.4 23.4 40.6 28.8 30.0 22.2 44.1 25.3
Change from 1009 baseline to:
1009 Week 4 24.3 21.1
(31.52, 17.04)
1.15
22.3 21.3
(28.69, 15.87)
1.04
18.2 19.0
(24.10, 12.39)
0.96
11.3 17.2
(16.70, 5.97)
0.66
13.3 18.4
(18.94, 7.73)
0.72
2.6 22.3
(9.69, 4.58)
0.11
15.3 21.0
(17.89, 12.65)
0.73
1009 Week 8 20.4 20.5
(27.47, 13.36)
0.99
23.6 22.5
(30.78, 16.40)
1.05
16.2 21.5
(22.78, 9.68)
0.75
8.0 12.4
(11.96, 4.03)
0.64
7.6 20.0
(13.78, 1.33)
0.38
1.8 24.8
(6.49, 10.04)
0.07
12.4 22.1
(15.19, 9.55)
0.56
1009 Week 32 10.6 24.9
(23.37, 2.26)
0.42
25.9 32.4
(42.53, 9.25)
0.80
16.6 31.7
(31.41, 1.69)
0.52
17.8 27.2
(37.22, 1.63)
0.66
9.3 22.2
(21.16, 2.50)
0.42
12.9 29.6
(18.18, 43.96)
0.44
14.0 29.1
(20.19, 7.73)
0.48
Data shown for all patients in the ITT population, reporting within 70 days of last dose.
* Increase denotes improvement.
y Decrease denotes improvement.
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mab exposure lead to new or unanticipated changes in the safety or
AE proﬁle for tanezumab. No alterations in verbal learning or
memory status, as indicated by the lack of changes in the HVLT-R
and neurologic examinations, were observed during long-term
treatment with tanezumab, which is consistent with earlier
studies16.
In this study, AEs suggestive of abnormal peripheral sensation
and attributed to study drug were rated as mild in severity and,
similar to earlier reports14,16, most were generally transient (range
1e331 days). Incidence of the AEs of abnormal peripheral sensation
was similar across each 8-week interval. Thus, the frequency of AEs
of abnormal peripheral sensation is unchanged as patients
continued to receive additional tanezumab infusions to relieve
chronic OA knee pain.
As noted, two patients developed neutralizing antitanezumab
antibodies. The AEs experienced by the two ADA-positive patients
were not serious andwere considered not related to the study drug.
The pharmacokinetic proﬁles for the ADA-positive patients were
similar to patients negative for ADA. The clinical relevance of
neutralizing antitanezumab antibodies is not known at this time. It
is common for patients treated with fully humanized monoclonal
antibodies or chimeric monoclonal antibodies to develop ADA19e21.
For example, 8% of patients treated with the chimeric anti-tumor
necrosis factor antibody inﬂiximab (plus methotrexate) developed
anti-inﬂiximab antibodies22, although a larger percentage of
patients (43%) has been reported more recently23. A correlationbetween anti-monoclonal antibodies and reductions in efﬁcacy has
not been deﬁnitively established in patients with rheumatoid
arthritis, cancer, or psoriasis24e26, but the development of ADAmay
have a clinical relevance, since a reduction in efﬁcacy has been
noted23. Further clinical studies with tanezumab in OA as well as
other indications may provide additional insight.
Tanezumab provided continued effective relief of the pain
associated with knee OA for as long as 56 weeks in this study with
effectiveness similar to that noted in earlier tanezumab studies in
patients with OA14e16. In both the current and previous studies,
tanezumab provided a signiﬁcant improvement in the relief of OA
knee pain following a single injectionwith reductions of 45% to 62%
in pain16. Symptomatic improvement was rapid in onset, with
signiﬁcant improvement reported within 1 week16, and sustained,
lasting up to 8 weeks after each infusion and maintained for up to
56 weeks, the latest time point in this study, and at 72 weeks when
Study 1008 is also considered.
This study has a number of strengths, including the use of
a novel agent, tanezumab, to reduce pain in knee OA, and thorough
clinical evaluation of the study patients. Limitations of the study
include the relatively small number of patients treated with
multiple doses over long periods of follow-up. The few patients
who received the longest treatment may not be representative. A
second limitation is the absence of an active or placebo comparator,
which precludes comparisons during long-term tanezumab use.
Third, the open-label design of the study limits the overall
conclusions that can be made about the use of tanezumab at this
T.J. Schnitzer et al. / Osteoarthritis and Cartilage 19 (2011) 639e646 645time. Finally, because patients experiencing any AE or condition
during controlled tanezumab studies that, in the opinion of the
investigator, excluded the patient from participating in the open-
label extension, the patient population did not include patients
who demonstrated sensitivity to tanezumab during earlier clinical
trials. As a result, this study may be somewhat biased toward
under-reporting AEs. Future clinical studies of the clinical efﬁcacy
and safety of tanezumab in this indication and inclusion of an active
comparator should provide further insight into the efﬁcacy and
safety of tanezumab as a potential therapy for the treatment of OA
knee pain.
Since the completion of this study and through May 24, 2010, 16
subjects participating in one of 13 Phase III studies of OA of the hip
and knee developed progressively worsening OA associated with
radiographic evidence of bone necrosis which required total joint
replacements. The affected joints included the knee, hip, or
shoulder, (predominately unilateral involvement) with over
one-half of the cases occurring in a joint other than the index joint
under evaluation in the study. These 16 events led the FDA on June
22, 2010 to put the OA clinical program for tanezumab on clinical
hold until more information can be obtained to determine the true
incidence and the causality of these events. On July 19, 2010 the
FDA also added Phase II studies with tanezumab in chronic low
back pain and diabetic peripheral neuropathy to the clinical hold.
No cases of progressively worsening OA associated with
radiographic evidence of bone necrosis were reported in the
current study.
In summary, repeated injections of tanezumab (50 mg/kg) in
individuals with moderate to severe knee OA continued to provide
pain relief and to improve function with a low incidence of side
effects. Additional studies are warranted to deﬁne further the
efﬁcacy and duration of pain reductionwith this novel agent as well
as to provide a more complete assessment of long-term safety.Contributions
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